Envisia reports positive interim results from Phase II trial of ENV515 in glaucoma

US-based clinical-stage biotechnology firm Envisia Therapeutics has reported positive interim results from the second cohort of the ENV515 (travoprost XR) Phase II trial to treat patients with glaucoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news